| Daratumumab studied in …STUDIED_INderived200 of 261show all (up to 200) |
|---|
| → studied in | NCT06055075Phase 1/Phase 2 · terminated A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07222761Phase 3 · recruiting A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · 261 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07391657Phase 3 · recruiting A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04181827Phase 3 · active not recruiting A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04722146Phase 1 · active not recruiting A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04973605Phase 1/Phase 2 · recruiting A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05050097Phase 1 · active not recruiting A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04108195Phase 1 · active not recruiting A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04133636Phase 2 · active not recruiting A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05083169Phase 3 · active not recruiting A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05438043Phase 3 · active not recruiting A Study of Daratumumab · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05455320Phase 3 · active not recruiting A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05552222Phase 3 · recruiting A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05572229Phase 2 · active not recruiting Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05623020Phase 3 · recruiting A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05907759Phase 2 · recruiting Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease · 261 trials list this drug (139 active) | — | — | Primary Effusion Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06577025Phase 2 · active not recruiting A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06768489Phase 1 · recruiting A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma,Smoldering Multiple Myeloma,AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07393282Phase 3 · recruiting A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) · 261 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07665450Phase 3 · recruiting A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03899155Phase 2 · recruiting Pan Tumor Rollover Study · 261 trials list this drug (139 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07095452Phase 2/Phase 3 · recruiting A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04661137Phase 2 · recruiting A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07830485Phase 2 · not yet recruiting CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04933539Phase 2 · active not recruiting Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04910568Phase 1 · recruiting A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07623798Phase 3 · recruiting A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04635189Phase 2 · active not recruiting Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03004287Phase 2 · active not recruiting 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04497961Phase 2 · active not recruiting A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04756401Phase 2 · active not recruiting Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06182774Phase 3 · recruiting Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06615479Phase 3 · recruiting A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06827860Phase 2 · recruiting Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06953960Phase 1/Phase 2 · recruiting A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04972942Phase 1 · recruiting Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma · 261 trials list this drug (139 active) | — | — | T Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07555938Phase 3 · recruiting Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04124497Phase 2 · active not recruiting A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04915248Phase 2 · recruiting Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. · 261 trials list this drug (139 active) | — | — | Plasmablastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07793422Phase 3 · not yet recruiting Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis · 261 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07681596Phase 1/Phase 2 · recruiting A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05020236Phase 3 · recruiting A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04151667Phase 2 · completed Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03937635Phase 3 · recruiting Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma · 261 trials list this drug (139 active) | — | — | Smoldering Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06042725Phase 1 · active not recruiting MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07341867Phase 1 · recruiting Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype · 261 trials list this drug (139 active) | — | — | Multiple Myeloma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05259839Phase 1 · active not recruiting A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07764861Phase 2 · not yet recruiting A Open-Label Phase in Participants With Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07764978Phase 3 · recruiting Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07513129Phase 1 · recruiting Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma · 261 trials list this drug (139 active) | — | — | Lymphoma,T Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06918002Phase 3 · recruiting Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07221032Phase 1 · not yet recruiting FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03346135Phase 2 · active not recruiting Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06287944Phase 1 · recruiting 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome · 261 trials list this drug (139 active) | — | — | Acute Lymphoblastic Leukemia,Myelodysplastic Syndrome,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07740486Phase 3 · not yet recruiting A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07072585Phase 2/Phase 3 · not yet recruiting Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) · 261 trials list this drug (139 active) | — | — | T Lymphoblastic Leukemia/Lymphoma,T Acute Lymphoblastic Leukemia,T Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06413498Phase 3 · active not recruiting A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04140162Phase 2 · active not recruiting Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07335887Phase 2 · recruiting Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis · 261 trials list this drug (139 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07728188Phase 3 · not yet recruiting A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06892522Phase 1/Phase 2 · recruiting A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02343042Phase 1/Phase 2 · recruiting Selinexor and Backbone Treatments of Multiple Myeloma Patients · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07649525Phase 3 · recruiting Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level · 261 trials list this drug (139 active) | — | — | Multiple Myeloma,Plasma Cell Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05451771Phase 1/Phase 2 · active not recruiting Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis · 261 trials list this drug (139 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03283917Phase 1 · completed Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis · 261 trials list this drug (139 active) | — | — | Primary Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06483139completed Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05137054Phase 1 · recruiting A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06192979NA · recruiting Optimize First-line Treatment for AL Amyloidosis With t (11; 14) · 261 trials list this drug (139 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06083922Phase 2 · recruiting A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) · 261 trials list this drug (139 active) | — | — | Multiple Myeloma,Monoclonal Gammopathy of Renal Significance | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04775550Phase 2 · active not recruiting DARA RVD For High Risk SMM · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06015724Phase 2 · active not recruiting Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer · 261 trials list this drug (139 active) | — | — | Lung Non-Small Cell Carcinoma,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07671287Phase 3 · not yet recruiting GMMG-HD11/DSMM XXI/64007957MMY3010 · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05749276Phase 1 · recruiting Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM) · 261 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06785415Phase 1/Phase 2 · recruiting Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04068597Phase 1/Phase 2 · recruiting Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies · 261 trials list this drug (139 active) | — | — | Multiple Myeloma,Non-Hodgkin Lymphoma,Acute Myeloid Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01415882Phase 2 · completed Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03901963Phase 3 · completed A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03651128Phase 3 · completed Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07428369Phase 2/Phase 3 · withdrawn A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03556332Phase 2 · active not recruiting A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01946477Phase 2 · completed Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03447808Phase 1 · completed Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia · 261 trials list this drug (139 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06348147Phase 2 · withdrawn Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04176718Phase 2 · active not recruiting Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06974786Phase 2 · recruiting Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03652064Phase 3 · completed A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04139304early Phase 1 · recruiting A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma · 261 trials list this drug (139 active) | — | — | Plasmablastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05434689Phase 1/Phase 2 · active not recruiting COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03290950Phase 2 · active not recruiting A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04302324Phase 2 · active not recruiting A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04824794Phase 1/Phase 2 · terminated GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies · 261 trials list this drug (139 active) | — | — | Acute Myeloid Leukemia,Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05497804Phase 2 · active not recruiting Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06570915Phase 2 · withdrawn Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy · 261 trials list this drug (139 active) | — | — | Adult Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05849610Phase 2 · active not recruiting Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma · 261 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05527340Phase 2 · active not recruiting Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients. · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03477539Phase 2 · completed Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04922723Phase 1/Phase 2 · active not recruiting Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma · 261 trials list this drug (139 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03622775Phase 2 · terminated Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02316106Phase 2 · completed A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04246047Phase 3 · active not recruiting Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06868654Phase 3 · active not recruiting China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06868667Phase 3 · active not recruiting Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06679101Phase 3 · recruiting A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05392946Phase 1/Phase 2 · active not recruiting Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04166565Phase 2 · active not recruiting Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease · 261 trials list this drug (139 active) | — | — | Multiple Myeloma,Extraosseous Plasmacytoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03763162Phase 2 · active not recruiting Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07107529Phase 2 · recruiting Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03500445Phase 2 · active not recruiting Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04667663Phase 1 · active not recruiting CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma. · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02626481Phase 2 · completed Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04925193Phase 2 · active not recruiting Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04975997Phase 3 · active not recruiting Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05898646Phase 2 · recruiting Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial · 261 trials list this drug (139 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03236428Phase 2 · active not recruiting Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Smoldering Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06932562Phase 3 · recruiting A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07452198Phase 3 · recruiting A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04268498Phase 2 · active not recruiting A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02773030Phase 1/Phase 2 · active not recruiting A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05257083Phase 3 · active not recruiting A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06353022Phase 2 · active not recruiting Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05896228Phase 2 · recruiting Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04656951Phase 2 · active not recruiting Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03589222Phase 2 · active not recruiting SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04270175Phase 2 · active not recruiting Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab · 261 trials list this drug (139 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06549634completed Biomarkers of AKI in Patients Receiving Daratumumab · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06100237Phase 2 · recruiting Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03710603Phase 3 · active not recruiting Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07400744Phase 1 · not yet recruiting A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05590377Phase 1/Phase 2 · terminated A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05556616Phase 1 · terminated A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04230304Phase 2 · terminated Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study · 261 trials list this drug (139 active) | — | — | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05695508Phase 2 · recruiting GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01665794Phase 1/Phase 2 · completed Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03180736Phase 3 · completed Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04009109Phase 2 · active not recruiting Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05182073Phase 1 · completed FT576 in Subjects With Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03829371Phase 4 · active not recruiting STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03734198Phase 2 · active not recruiting Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction · 261 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02060188Phase 2 · completed A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread · 261 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03837509Phase 1/Phase 2 · terminated INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05363111Phase 1 · recruiting Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07075510Phase 1/Phase 2 · recruiting Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders · 261 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01592370Phase 1/Phase 2 · completed An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Hodgkin Lymphoma,Multiple Myeloma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02252172Phase 3 · completed Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02136134Phase 3 · completed Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02195479Phase 3 · completed A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05835726completed Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients. · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03314181Phase 2 · active not recruiting A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05308654Phase 1 · active not recruiting A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07045909Phase 2 · recruiting Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) · 261 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04052880Phase 2 · active not recruiting Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06464991Phase 3 · recruiting A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07026604early Phase 1 · not yet recruiting Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy Study · 261 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07021677Phase 2 · recruiting Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia" · 261 trials list this drug (139 active) | — | — | T Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06409702Phase 4 · recruiting Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07015021NA · not yet recruiting The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03012880Phase 2 · completed Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06119685Phase 1/Phase 2 · recruiting IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers · 261 trials list this drug (139 active) | — | — | Liquid Tumor,Multiple Myeloma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03432741Phase 1 · terminated Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer · 261 trials list this drug (139 active) | — | — | Breast Carcinoma,Hodgkin Lymphoma,Non-Hodgkin Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03384654Phase 2 · completed A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma · 261 trials list this drug (139 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03490344Phase 2 · completed Short Course Daratumumab in Patients With Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03537599Phase 1/Phase 2 · terminated Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant · 261 trials list this drug (139 active) | — | — | Acute Myeloid Leukemia, Myelodysplasia-Related,Adult Acute Myeloid Leukemia,Childhood Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04892264Phase 1 · terminated Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03158688Phase 3 · completed Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04892446Phase 2 · terminated Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02076009Phase 3 · completed A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03412565Phase 2 · completed A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01998971Phase 1 · completed A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06931704Phase 2 · not yet recruiting Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA) · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06140966Phase 2 · recruiting Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02541383Phase 3 · completed A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04251065Phase 2 · terminated Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH · 261 trials list this drug (139 active) | — | — | T-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06895512Phase 3 · not yet recruiting A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05486481Phase 1/Phase 2 · withdrawn Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) · 261 trials list this drug (139 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04304144Phase 2 · completed A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis · 261 trials list this drug (139 active) | — | — | AL Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04700176Phase 2 · terminated A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05243342Phase 1 · completed A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02413489Phase 2 · terminated An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma · 261 trials list this drug (139 active) | — | — | Lymphoma,Follicular Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02874742Phase 2 · completed Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03357952Phase 2/Phase 3 · completed A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02918331Phase 1 · completed A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03768960Phase 4 · completed A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03473730early Phase 1 · completed Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer · 261 trials list this drug (139 active) | — | — | Malignant Urinary System Neoplasm,Bladder Urothelial Carcinoma,Clear Cell Renal Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04782687Phase 2 · active not recruiting Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma,Plasma Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02807558Phase 2 · completed A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome · 261 trials list this drug (139 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03989414Phase 1/Phase 2 · active not recruiting A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06697483NA · recruiting Risk Stratification and MRD-driven Maintenance for MM After ASCT · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06636552Phase 2 · recruiting An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L · 261 trials list this drug (139 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05284591completed Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv) · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06187441Phase 3 · recruiting FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06505369Phase 2 · recruiting Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03439293Phase 2 · completed A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04352205Phase 2 · terminated Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03942224Phase 2 · unknown Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06232707Phase 3 · withdrawn A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03234972Phase 3 · completed A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03188172Phase 2 · unknown MUK Nine b: OPTIMUM Treatment Protocol · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03035357Phase 2 · withdrawn Neoadjuvant Listeria or Daratumumab in Prostate Cancer · 261 trials list this drug (139 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03177460Phase 1 · completed Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer · 261 trials list this drug (139 active) | — | — | Prostate Adenocarcinoma,Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04407442Phase 2 · terminated Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab · 261 trials list this drug (139 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |